Medical researchers and patients alike are now pinning their hopes on a drug called donanemab. This medication is expected to fight cognitive decline, offering hope to those facing Alzheimer’s.

Donanemab’s mechanism of action revolves around targeting a protein that accumulates in the brains of Alzheimer’s disease patients. By clearing this protein, the drug can slow the condition’s progression, especially in its early stages. Donanemab trials indicate that it may reduce the disease pace by approximately one-third.

However, medical researchers have not concluded that donanemab is a cure for Alzheimer’s disease. Instead, antibody medicine can serve as a critical weapon to slow the disease’s progression at an early stage of the condition. The drug’s efficacy has been demonstrated exclusively in Alzheimer’s disease and does not exhibit the same effect in other types of dementia like vascular dementia.

The excitement surrounding donanemab has prompted the UK’s drugs watchdog to initiate an assessment of its possible use within the National Health Service (NHS). If approved, the drug could become a crucial asset in the healthcare system to combat Alzheimer’s disease.

However, donanemab is not without risks. Some patients in the trials experienced brain swelling.

Analysis of the trial results revealed that individuals with early-stage disease and lower baseline levels of brain amyloid experienced greater clearance of amyloid plaques on brain scans. Patients have reported retaining more of their day-to-day functionality, such as engaging in discussions about current events, answering phone calls, and pursuing hobbies.

The pace of Alzheimer’s progression, assessed based on individuals’ functional capabilities, showed a notable slowdown. The drug’s effect translated into a 20-30% deceleration in disease progression. Notably, a subset of patients deemed more likely to respond to the treatment experienced even more significant benefits, with the disease’s progression slowing by an impressive 30-40%.

Former British Prime Minister David Cameron expressed the need for directing resources towards further research on what he called a “statin for the brain” during his conversation with BBC Radio 4’s PM programme.

The former premier also affirmed that the British government should be willing to invest in new treatments, given the significant number of dementia patients in the country and the potential cost savings from effective care.